Abstract: A sealable connection system is provided. The system can include a connection assembly including a housing and at least one ferrule positioned within the housing. An inner surface of the housing can be arranged to mate with and secure to an outer surface of a sensor assembly. The at least one ferrule can be arranged to engage with the sensor assembly as the housing is secured to the sensor assembly. The system can also include a fiber optic cable assembly. The fiber optic cable assembly can include a fiber optic cable extending through the housing and the at least one ferrule. The fiber optic cable can also be surrounded, at least along a length of the fiber optic cable within the connection assembly, by a fiber optic cable cover. The sealable connection system is provided to hermetically connect the fiber optic cable assembly to a sensor assembly.

Abstract: An excavation machine is provided. The excavation machine includes an excavation device and an excavation device drive system that powers the excavation device to move cutting tools, wherein the excavation device drive system includes an electric motor and a motor controller, wherein the motor controller is programmed to control the speed of the excavation device drive system. The motor controller sets the speed of the excavation device drive system at a predetermined excavation speed based on a predetermined target power, the predetermined target power being associated with a target torque generated by the electric motor. The speed of the excavation device drive system is set at a predetermined first excavation speed when a power transmitted to the electric motor is below the predetermined target power and at a predetermined second excavation speed to maintain the power transmitted to the electric motor at the predetermined target power.

Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Abstract: A sealable connection system is provided. The system can include a connection assembly including a housing and at least one ferrule positioned within the housing. An inner surface of the housing can be arranged to mate with and secure to an outer surface of a sensor assembly. The at least one ferrule can be arranged to engage with the sensor assembly as the housing is secured to the sensor assembly. The system can also include a fiber optic cable assembly. The fiber optic cable assembly can include a fiber optic cable extending through the housing and the at least one ferrule. The fiber optic cable can also be surrounded, at least along a length of the fiber optic cable within the connection assembly, by a fiber optic cable cover. The sealable connection system is provided to hermetically connect the fiber optic cable assembly to a sensor assembly.

Abstract: A sealable connection system is provided. The system can include a connection assembly including a housing and at least one ferrule positioned within the housing. An inner surface of the housing can be arranged to mate with and secure to an outer surface of a sensor assembly. The at least one ferrule can be arranged to engage with the sensor assembly as the housing is secured to the sensor assembly. The system can also include a fiber optic cable assembly. The fiber optic cable assembly can include a fiber optic cable extending through the housing and the at least one ferrule. The fiber optic cable can also be surrounded, at least along a length of the fiber optic cable within the connection assembly, by a fiber optic cable cover. The sealable connection system is provided to hermetically connect the fiber optic cable assembly to a sensor assembly.

Abstract: The invention provides methods and compositions to enhance the efficiency and sensitivity of molecular inversion probe (MIP) reactions. Probes include elements that allow MIP ends to abut for ligation while avoiding the possibility of polymerase strand displacement errors. Elements facilitate multiplexed detections, including MIP reaction product detections employing next generation sequencing (NGS) techniques.

Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.

Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Abstract: A debug test system is provided. The debug test system includes one or more interfaces configured to communicate with a target system and processing circuitry configured to control the one or more interfaces. Further, the processing circuitry is configured to receive information about an operation state of the target system from the target system and to generate control information for the target system to adjust a debug session on the target system. The processing circuitry is further configured to transmit the control information to the target system.

Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Abstract: Systems and methods for automated aggregated content commenting are disclosed herein. Such a system can include a memory including a content database; an evaluation criteria database; and a comment database. The system can include at least one server. The at least one server can: receive a content identifier; receive a user identifier; provide a representation of the piece of content to the user; receive a comment from the user identifying a portion of the piece of content; generate a portion of the comment database linked to the user and the content; generate an entry in the portion of the comment database linked to the user and the content; and store the comment in the entry in the portion of the comment database.

Abstract: The present invention relates to compounds of formula I wherein R, R4 and Q are each as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 pathway (HSF1 pathway). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.

Abstract: Systems and methods for automated aggregated content commenting are disclosed herein. Such a system can include a memory including a content database; an evaluation criteria database; and a comment database. The system can include at least one server. The at least one server can: receive a content identifier; receive a user identifier; provide a representation of the piece of content to the user; receive a comment from the user identifying a portion of the piece of content; generate a portion of the comment database linked to the user and the content; generate an entry in the portion of the comment database linked to the user and the content; and store the comment in the entry in the portion of the comment database.

Abstract: Systems and methods for automated aggregated content commenting are disclosed herein. Such a system can include a memory including a content database; an evaluation criteria database; and a comment database. The system can include at least one server. The at least one server can: receive a content identifier; receive a user identifier; provide a representation of the piece of content to the user; receive a comment from the user identifying a portion of the piece of content; generate a portion of the comment database linked to the user and the content; generate an entry in the portion of the comment database linked to the user and the content; and store the comment in the entry in the portion of the comment database.

Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Abstract: The disclosed principles provide an improved waxing system, apparatus, and related waxing methods, having a mechanical reaching attachment to be attached thereto, and thus provide additional reach and leverage for removing the waxing strip. In one embodiment, a waxing system comprises at least one waxing strip each comprising at least one waxing side and at least one attachment area located proximate an attachment end of each waxing strip. The at least one waxing side may be configured to receive waxing material thereon to remove body hair. The waxing system may also comprise at least one attachment device located in a corresponding at least one attachment area. In addition, the waxing system may comprise at least one removal device coupled to a corresponding at least one attachment device and configured for grasping by a user to remove the at least one waxing strip from a body during hair removal.